The Ministry of Environment, Forestry and Tourism (MEFT), through the Environmental Compliance Consultancy, has approved ReconAfrica’s application for an Environmental Clearance Certificate (ECC).
In a media statement issued on Friday, Environmental Commissioner, Timoteus Mufeti, said ReconAfrica’s next phase is to drill an exploration and appraisal oil and gas well in the Kavango Basin.
“As part of the progressive processes of de-risking the Kavango Sedimentary Basin (KSB), ReconAfrica is proposing to drill prioritised exploration and appraisal wells designed to confirm the existence of economic oil and gas resources,” Mufeti said.
The environment commissioner stated that the objectives of the proposed exploration and appraisal wells drilling programme is to continue with the search for oil and gas in the Kavango sub-basin and the associated sub-basins, and to identify potentially commercial petroleum systems.
Based on the submitted reports, the previous studies undertaken in the area since 2018, as well as the experiences, environment monitoring by MEFT, the Environmental Compliance Consultancy through systemic assessment is convinced that the potential negative impacts to the individual drilling sites will be low, he said.
Speaking in an interview with Nampa on Thursday, ReconAfrica Director of Communications and Stakeholder Relations, Ndapewoshali Shapwanale said the drilling is to commence from 04 July 2023 to 04 July 2026.
“The primary objective of the drilling programme is to establish commercial accumulations of oil and natural gas and liquids, which were identified in the first three stratigraphic test wells,” Shapwanale said.
Moreover, Shapwanale added that the management’s current focus in the third and fourth quarter of 2023 is developing and prioritising its prospect inventory, in order to execute a multi-well drilling programme targeting both primary plays; the Damara Fold Belt and the Karoo Rift Basin, with initial emphasis on the Damara Fold Belt as detailed in the company’s 26 June 2023 news release.
The national senior women’s football team, the “Brave Gladiators”, will have a two-goal advantage on Tuesday to their return leg of the 2024 Women’s Olympic Games qualifier against Equatorial Guinea.
The Brave Gladiators outclass their opponents 2-0 in the first leg of their Olympic qualifiers at the FNB Stadium in Johannesburg on Thursday.
The 2024 Women’s Olympic Games qualifiers are being used to select two teams that will represent the continent in Paris, France in 2024. The winner of the first-round ties will advance to the second round, where they will face Morocco in October this year.
In their opening match of the qualifiers on Thursday, the gladiators put up an outstanding performance, which saw their talisman, Zenatha Coleman, opening the score in the 34th minute to take the game to the half-time break with a 1-0 lead.
In the second half, Coleman’s brilliant play once again saw her creating an assist for Ivone Kooper, who double the score in the 52nd minute to put the Namibian outfit at an advantage ahead of their return leg in Malabo.
In an interview after the match, gladiators’ head coach, Paulus Shipanga, said playing against a team that is better than them is always a challenge but patience and dedication got them through.
“I am proud of the girls the way they played. I would have liked more goals but we need to be thankful for the ones we scored and played against players that are bigger than us in physique. You are not able to dominate them physically therefore we opted for speed which won us the game,” he said.
He added that his long-term goal is to build something for the next two or three years but with him just being an interim coach that would be difficult to execute but he will do his best to give each player a playing opportunity.
The return leg of the 2024 Paris Olympic Games qualifiers is slated for Malabo Stadium in Malabo, Equatorial Guinea on 18 July 2023.
T11 male paralympic sprinters Chris Kinda (guided by Riwaldo Goagoseb) and Ananias Shikongo (guided by Even Tjiuiju) progressed to the semi-finals of the men’s T11 100 metres (m) after finishing second in their heats at the International Paralympic Committee (IPC) 2023 World Para Athletics Championships underway in Paris, France.
The T11 100m heats were held on Friday morning at the Charlety Stadium, where over 1 300 athletes from 107 nations are competing for 168 medals.
On Friday morning, Shikongo and Tjiuiju ran a seasonal best of 11.36 seconds to finish second in a photo finish behind Germany’s Marcel Boettger and his guide Alexander Kosenkow, who won that heat with the same time.
Meanwhile, Shikongo’s teammates Kinda and Goagoseb also finished second in their heat with a time of 11.76 seconds to see both runners progressing to the semi-finals.
Alfredo Bernardo, another T11 athlete, and his guide Hatago Murere, failed to reach the next round of the competition after finishing last in their heat with a time of 12.14 seconds.
Only the heat winner and the fastest seven runner-ups from the five heats progressed to the semi-finals slated for 20h35 Friday evening.
Another Namibian expected to compete on Friday evening is T12 female sprinter Lahja Ipinge and her guide Paulus Filippus, who will compete in the 100m heat, while T13 male sprinter Johannes Nambala will compete in the 400m heat.
The major international multi-sport event involves athletes with a range of disabilities and is governed by the International Paralympic Committee.
The Centre of Disease Control and Prevention (CDC) on Friday handed over multi-media technology equipment to the Ministry of Health and Social Services (MoHSS).
Speaking at the handover ceremony in the capital, MoHSS Executive Director, Ben Nangombe, expressed gratitude on behalf of the ministry.
“This momentous occasion marks a significant milestone in our journey towards improving public health communication. The media equipment we receive today serves as a catalyst for innovation, collaboration and positive change,” Nangombe said.
He added that with these state-of-the-art tools at their disposal, they are equipped to deliver impactful health messages to the communities with greater clarity and effectiveness.
Furthermore, the executive director extended his heartfelt gratitude to the CDC for recognising the importance of media resources in advancing public health.
At the same ceremony, CDC Country Director Brian Baker stated that the American government, through the CDC, is a proud to partner with the MoHSS to have the equipment needed to produce high quality communications that help convey important health messages.
Baker added that CDC has supported the MoHSS for over 20 years and that over the years, CDC has worked with the MoHSS on numerous public health messaging campaigns that have helped improve outcomes in the country on healthcare needs such as HIV and AIDS, COVID-19, hepatitis E, anthrax, and Crimean-Congo hemorrhagic fever.
“I congratulate the MoHSS on working to strengthen its public health message capacity, public health messaging is a continental need and CDC Namibia is committed to support the MoHSS in the important area of multi-media,” he said.
Roseau, July 13, 2023 (GLOBE NEWSWIRE) — Nigeria is currently facing economic challenges, despite having the largest economy in Africa. The country’s debt grew a staggering 500 per cent under the former President, Muhammadu Buhari. The World Bank revised Nigeria’s gross domestic product (GDP) earlier this year, in the recent Nigeria Development Update (NDU).
The NDU report is released biannually by the World Bank and evaluates Nigeria’s current economic and social developments and long-term prospects on a global scale. The report also focuses on Nigeria’s economic and policy issues and analyses medium-term development challenges.
These economic and political challenges are causing Nigerian citizens to face great uncertainty, many of whom are hoping to see positive changes with the new president, Bola Ahmed Tinubu.
Nigerians are continuously seeking alternative methods to protect themselves and their families’ future, and one economical way of achieving this can be through the investment migration industry. Several factors influence Nigerians’ choices in selecting a host country’s CBI programme. Nigerians desire their dual citizenship to ensure economic and political stability in a host country that creates safety and security for both personal and business activities.
The Commonwealth of Dominica offers Nigerians opportunities that include encouraging and supporting business growth and a family-friendly environment.
Nigerians can access these opportunities through Dominica’s Citizenship by Investment (CBI) Programme and obtain dual citizenship in exchange for contributing investments towards one of the programme’s investment options. There are additional requirements when applying for dual citizenship, which include background and due diligence checks that may have additional fees applied.
Access to quality healthcare and educational facilities is important for Nigerians and their families, these facilities have international standards that offer advanced medical practices and schools that encourage further studies in Dominica or anywhere else around the world.
Dominica’s dual citizenship has one of the most affordable CBI programmes in the Eastern Caribbean region.
How do Nigerians benefit from Dominica’s CBI Programme?
Dual citizenship is a key to opening possibilities that come with Dominica’s dual citizenship, Nigerians can become part of the greater global community and increase their chances of ease of access to global markets that they were unable to previously.
Dominica is an English-speaking country, making it easier to communicate with the locals and with the Government of Dominica.
Nigerians can establish their businesses and expand their existing business ventures in Dominica. This will open more possibilities for creating permanent jobs and support local entrepreneurs with their small businesses.
Dominica offers offshore financial services to Nigerians who want to make international transactions and remittances back home. The CBI programme forms avenues for wealth management services and opportunities to protect assets and generational wealth.
The country also has many projects that are currently running through Dominica’s CBI, which will yield profitable results in their developing stages once completed, these will support the economic development of the country and improve the livelihoods of all citizens.
Nigerians can visit and live in Dominica with their family members whom they had applied for dual citizenship. Dominica is a tropical island paradise with picturesque landscapes and endless leisure activities for the whole family to enjoy.
Nigerian applicants are not required to undergo a series of exams to apply, nor do they need to live in Dominica for some time to qualify for dual citizenship.
Investment options available for dual citizenship
Nigerians can choose from the Economic Diversification Fund or Dominica’s Real Estate investment options. These investment options are also efficient for large families.
The Economic Diversification Fund (EDF) is a non-refundable contribution towards financially supporting private or public initiatives in Dominica. These initiatives include construction and development projects, renovation of hospitals, ecotourism, and agriculture. The contribution funds depend on the number of family members included in the applicant:
The main applicant is ₦77,000,000 (US$100,000)
A married couple’s contribution is ₦15,000,000 (US$150,000)
A family of four contributions is ₦134,000,000 (US$175,000)
For any additional family member under 18 years of age is ₦19,000,000 (US$25,000)
And for any additional family member 18 years of age and over is ₦38,000,000 (US$50,000)
Dominica’s Real Estate investment option has government-approved luxurious properties around the country that offer exceptional returns on investments. From ₦153,000,000 (US$200,000). Any real estate properties purchased must own for a minimum of three years, or five years should the future purchaser be a CBI applicant. Dominica’s real estate fees are as follows:
The main applicant is ₦19,000,000 (US$25,000)
For a family of four is ₦26,000,000 (US$35,000)
For a family of five is ₦38,000,000 (US$50,000)
For any additional family member is ₦19,000,000 (US$25,000)
Dominica has award-winning luxury properties such as the Secret Bay. The eco-luxury resort featured in Travel + Leisure as the ‘#1 Best Resort Hotel in the Caribbean, Bermuda, and the Bahamas‘ in 2022 and is expanding its amenities and villas that are expected to be available from 2025, Dominica’s CBI investors contribute to Secret Bay’s success, as it offers high returns on investments. There are other luxury resorts and villas can cater to the needs of Nigerian investors’ long-term investment goals, such as Jungle Bay, and InterContinental Dominica Cabrits Resort and Spa.
Les deux sociétés vont collaborer à l’élaboration de logiciels destinés aux sociétés biotechnologiques et pharmaceutiques afin de créer plus rapidement des traitements améliorés pour les patients
SALT LAKE CITY, TORONTO et MONTRÉAL, 13 juill. 2023 (GLOBE NEWSWIRE) — Recursion (NASDAQ: RXRX), société biotechnologique au stade clinique chef de file dans le décodage biologique pour l’industrialisation de la découverte de médicaments, a annoncé aujourd’hui un investissement de 50 millions de dollars de NVIDIA, effectué sous forme de Placement privé dans les sociétés ouvertes (PPSO) Recursion a également annoncé son intention, en collaboration avec NVIDIA, d’accélérer le développement de ses modèles biologiques et chimiques basés sur l’IA afin de les optimiser et de les distribuer aux sociétés biotechnologiques en utilisant les services infonuagiques de NVIDIA.
« Notre collaboration avec NVIDIA représente l’union de deux sociétés de premier plan pour contribuer à résoudre l’un des plus grands défis au monde, la découverte de médicaments », a déclaré Chris Gibson, cofondateur et chef de la direction de Recursion. « Grâce à notre puissant ensemble de données et aux capacités informatiques accélérées de NVIDIA, nous avons l’intention de créer des modèles biologiques et chimiques de base, et ce, à une échelle sans précédent relativement à ce qui a été fait dans le domaine biologique ».
Recursion prévoit d’utiliser son vaste et exclusif ensemble de données biologiques et chimiques, dépassant 23 pétaoctets et 3 000 milliards de gènes et de relations des gènes et des composés consultables, afin d’accélérer la formation de modèles de base sur le nuage NVIDIA DGX en vue d’une éventuelle licence commerciale/diffusion sur BioNeMo, le service infonuagique de NVIDIA pour l’IA générative dans le domaine de la découverte de médicaments. NVIDIA aidera également à optimiser et à faire évoluer les modèles de base Recursion en s’appuyant sur la pile IA et l’expertise informatique complète de NVIDIA. BioNeMo a été annoncé au début de l’année comme un service infonuagique pour l’IA générative destinée à la découverte de médicaments, offrant des outils pour personnaliser et déployer rapidement des modèles biomoléculaires de pointe à l’échelle, spécifiques à un domaine, par le biais de services API en nuage. Recursion prévoit d’utiliser ce logiciel pour soutenir sa réserve de projets interne ainsi que ses partenaires actuels et futurs.
« L’IA générative est un outil innovant pour découvrir de nouveaux médicaments et traitements », a déclaré Jensen Huang, fondateur et chef de la direction de NVIDIA. « Nous sommes ravis de collaborer avec l’équipe de classe mondiale de Recursion, qui effectue un travail innovant en biologie et chimie numériques avec NVIDIA DGX et le logiciel NVIDIA AI afin d’accélérer le développement des plus grands modèles d’IA générative biomoléculaire au monde et la découverte de médicaments pour les sociétés biotechnologiques et pharmaceutiques »
Recursion, par l’acquisition récente de Valence Discovery, vise à accélérer le développement de nouvelles technologies pour alimenter l’industrie biopharmaceutique, tout en démocratisant l’accès aux modèles à grande échelle qui ont un impact maximal sur la découverte de médicaments.
À propos de Recursion Recursion (NASDAQ: RXRX) est une société biotechnologique en stade clinique, chef de file dans son domaine, qui décode les données biologiques pour industrialiser la recherche de nouveaux médicaments. Pour s’acquitter de sa mission, Recursion OS, plateforme mise au point à partir de technologies variées, étend continuellement l’un des plus grands ensembles de données chimiques et biologiques au monde. Recursion s’appuie sur des algorithmes d’apprentissage automatique sophistiqués pour extraire de son ensemble de données une collection de billions de relations consultables dans les domaines de la biologie et de la chimie, qui ne sont pas limitées par les biais humains. Par la possession et l’exploitation de l’un des plus puissants des superordinateurs au monde, et des recherches expérimentales menées une échelle expérimentale massive – jusqu’à des millions d’expériences en laboratoire humide hebdomadaires – et une échelle de calcul massive, Recursion unit la technologie, la biologie et la chimie pour faire progresser l’avenir de la médecine.
Recursion est basée à Salt Lake City, où elle est membre fondateur de BioHive, le collectif de l’industrie des sciences de la vie de l’Utah. Recursion possède également des bureaux à Toronto, Montréal et dans la région de San Francisco Bay. Pour en savoir plus, consultez le site www.Recursion.com, ou connectez-vous sur Twitter et LinkedIn.
Énoncés prospectifs
Ce document contient des informations qui incluent ou sont basées sur des « Énoncés prospectifs » au sens du Securities Litigation Reform Act de 1995, y compris, mais sans s’y limiter, celles concernant l’accélération et l’avancement du développement des modèles de fondation de l’IA, ainsi que l’optimisation, l’octroi de licences et la distribution de ces modèles; l’utilisation du logiciel BioNeMo pour soutenir le pipeline interne de Recursion ainsi que les partenaires industriels actuels et futurs de Recursion ; Recursion accélérant le développement de nouvelles technologies grâce à l’acquisition de Valence Discovery; ainsi que toutes les autres déclarations qui ne constituent pas des faits historiques. Les énoncés prospectifs peuvent inclure ou non des mots d’identification tels que « prévoit », « fera », « s’attend à », « anticipe », « a l’intention de », « croit », « potentiel », « continue » et des termes similaires. Ces énoncés sont soumis à des risques connus ou inconnus et à des incertitudes qui pourraient faire en sorte que les résultats réels diffèrent matériellement de ceux exprimés ou sous-entendus dans ces énoncés, y compris, mais sans s’y limiter : les défis inhérents à la recherche et au développement pharmaceutiques, y compris le calendrier et les résultats des programmes précliniques et cliniques, où le risque d’échec est élevé et où l’échec peut survenir à n’importe quel stade avant ou après l’approbation réglementaire en raison d’un manque d’efficacité suffisante, de considérations de sécurité ou d’autres facteurs; notre capacité à exploiter et à améliorer notre plate-forme de découverte de médicaments; notre capacité à obtenir un financement pour les activités de développement et d’autres objectifs de l’entreprise; le succès de nos activités de collaboration; notre capacité à obtenir l’approbation réglementaire des médicaments candidats et à les commercialiser; notre capacité à obtenir, maintenir et appliquer les protections de la propriété intellectuelle; les cyberattaques ou autres perturbations de nos systèmes technologiques; notre capacité à attirer, motiver et retenir des employés clés et à gérer notre croissance; l’inflation et d’autres questions macroéconomiques; et d’autres risques et incertitudes tels que ceux décrits sous la rubrique « Facteurs de risque » dans les documents que nous avons déposés auprès de la U. S. Securities and Exchange Commission. Securities and Exchange Commission, y compris notre rapport annuel sur le formulaire 10-K. Toutes les déclarations prospectives sont basées sur les estimations, projections et hypothèses actuelles de la direction, et Recursion ne s’engage pas à corriger ou mettre à jour ces déclarations, que ce soit à la suite de nouvelles informations, de développements futurs ou autres, sauf dans la mesure où la loi applicable l’exige.
